Magnetar Access & Blossom present
Reimbursement Pathways
for Psychedelic Therapies
Charting psychedelic therapy's path to European
healthcare coverage and mental health transformation.
Unlocking Reimbursement for Psychedelic Therapies
Psychedelic therapies show great potential for treating mental health conditions,
but challenges in regulatory approval, reimbursement models, and healthcare system
integration create significant access barriers.
Our report explores the current landscape,
identifies key obstacles, and presents actionable solutions to improve accessibility
and affordability across Europe.
Clinical Promise
Psychedelic therapies show high efficacy in clinical trials for PTSD, depression, and addiction.
Regulatory Challenges
Scheduling restrictions, clinical trial complexities, and policy gaps slow market adoption.
Reimbursement Barriers
High costs, complex treatment models, and lack of payer clarity create funding challenges.
Infrastructure & Training
Healthcare systems need trained therapists, dedicated spaces, and sustainable funding models.
Path Forward
Multi-stakeholder collaboration and policy reform can enable reimbursement and access.
"This report offers a thorough and comprehensive overview for those pursuing viable reimbursement pathways and sustainable market access for these promising treatments."
Dr Rayyan Zafar, UKRI Postdoctoral Fellow
Imperial College London, Centre for Psychedelic Research
"A thorough examination of Europe's complex reimbursement landscape that helps bridge the knowledge gap between U.S. and EU markets. Essential reading for developers planning global psychedelic therapy rollouts."
Lia Mix, LMFT, CPTR, Founder & CEO
Delphi
"A timely and insightful analysis of Europe's psychedelic reimbursement landscape. Important reading for Phase II/III developers planning European drug launches. It clearly outlines unique challenges, explores potential workarounds, and highlights trial design strategies to navigate the much‑discussed regulatory hurdles that could otherwise prove very costly."
Tom McDonald, Co-Founder & CEO
Clerkenwell Health
"This publication provides an important foundation for the next steps that involve strategies for how to ensure safe implementation of these new treatment paradigms in public health systems in Europe."
Dr David Erritzoe, Clinical Director & Clinical Senior Lecturer in Psychiatry
Imperial College London, Centre for Psychedelic Research
"If and when psychedelic therapies become approved, how can we ensure they reach those who need them most? This report envisions the crucial period that comes after regulatory approval. Offering an overview of how mental health care is currently reimbursed across Europe, the authors also map the roadblocks ahead, and most importantly, provide concrete solutions on how to overcome them. A must‑read for policymakers, payers, and all committed to making psychedelic‑assisted therapies available and accessible."
Joost Breeksema, Executive Director
OPEN Foundation
Report Resources
The following additional resources provide detailed supporting information, data, and context that complement the main report's findings and analysis.
The Road Ahead
This report provides a foundation for understanding how psychedelic therapies might be integrated into European healthcare systems. However, making these treatments accessible to patients will require sustained collaboration between stakeholders and creative solutions to address implementation challenges. We hope this analysis catalyses further work toward developing practical, sustainable access pathways.
Get Involved
Want to help advance psychedelic therapy access in Europe? Our team collaborates with stakeholders across the healthcare ecosystem to develop practical solutions for psychedelic therapy implementation. Contact us to explore how we can work together.
Work with Us Download the Report